1. Home
  2. PRHI vs LEXX Comparison

PRHI vs LEXX Comparison

Compare PRHI & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Presurance Holdings Inc.

PRHI

Presurance Holdings Inc.

N/A

Current Price

$0.77

Market Cap

14.2M

Sector

Finance

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$1.02

Market Cap

16.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRHI
LEXX
Founded
2009
2004
Country
United States
Canada
Employees
9
7
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2M
16.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRHI
LEXX
Price
$0.77
$1.02
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
30.8K
180.1K
Earning Date
05-13-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.46
52 Week High
$2.83
$1.67

Technical Indicators

Market Signals
Indicator
PRHI
LEXX
Relative Strength Index (RSI) 56.03 64.93
Support Level $0.54 $0.98
Resistance Level $0.87 $1.05
Average True Range (ATR) 0.10 0.10
MACD 0.02 0.01
Stochastic Oscillator 82.34 83.33

Price Performance

Historical Comparison
PRHI
LEXX

About PRHI Presurance Holdings Inc.

Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: